TITLE

Effectiveness of Intravenous Immunoglobulin Therapy for Skin Disease Other Than Toxic Epidermal Necrolysis: A Retrospective Review of Mayo Clinic Experience

AUTHOR(S)
Wetter, David A.; Davis, Mark Denis P.; Yiannias, James A.; Gibson, Lawrence E.; Dahl, Mark V.; El-Azhary, Rokea A.; Bruce, Alison J.; Lookingbill, Donald P.; Ahmed, Iftikhar; Schroeter, Arnold L.; Pittelkow, Mark R.
PUB. DATE
January 2005
SOURCE
Mayo Clinic Proceedings;Jan2005, Vol. 80 Issue 1, p41
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To examine retrospectively the use and effectiveness of intravenous Immunoglobulin (IVIg) treatment of various skin diseases, primarily immunobullous disease. PATIENTS AND IVIETHODS: We identified patients who had received IVIg therapy for skin disease between 1996 and 2003 at the Mayo Clinic in Rochester, Minn, Scottsdale. Ariz, and Jacksonville. Fla. and retrospectively reviewed their medical records. RESULTS: Eighteen patients were treated with IVIg for various skin diseases: immunobullous disease in 11 adults (pemphigus vulgaris [7 patients], bullous pemphigold [3], and cicatricial pemphigoid [1]): dermatomyositis (2); mixed connective tissue disease (1): chronic urticaria (1); scleromyxedema (1); leukocytoclastic vasculitis (1); and linear IgA bullous disease (1). Responses of patients by type of disease were as follows: pemphigus vulgaris, 1 partial response (PR) and 6 no response (NR); bullous pemphigold, 1 complete response (CR) and 2 NR; cicatricial pemphigold, 1 NR; dermatomyositis, 1 CR and 1 PR; mixed connective tissue disease, 1 CR; chronic urticaria, 1 CR; sclero-myxedema, 1 CR; leukocytoclastic vasculitis, 1 PR; and linear IgA bullous disease, 1 CR. Six patients (33%) experienced CR, (17%) had PR, and 9 (50%) had NR to IVIg therapy. All 9 non-responders were adult patients with immunobullous disease. CONCLUSION: Although this was a retrospective study of a small cohort of a mixture of patients, the findings emphasize that our experience with IVIg treatment for skin disease, particularly immunobullous disease, is less favorable than that reported previously. Further studies are needed to verify the efficacy of IVIg for skin disease.
ACCESSION #
15661392

 

Related Articles

  • Editorial.  // Acta Dermato-Venereologica;Nov2003, Vol. 83 Issue 6, p402 

    This article discusses the value of immunoglobulin therapy in dermatology. High-dose intravenous immunoglobulin therapy (HDIVIG) has recently entered dermatology and is used in selected cases, when the usual immunosuppressive therapy fails. HDIVIG is a very expensive treatment and not without...

  • Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Paradela, S.; Mart�nez-G�mez, W.; Fern�ndez-Jorge, B.; Casti�eiras, I.; Yebra-Pimentel, T.; Llinares, P.; Capdevila, E. Fonseca // Lupus;2007, Vol. 16 Issue 9, p741 

    The term �Acute Syndrome of Apoptotic Pan-Epidermolysis� (ASAP) designs clinical entities characterized by massive cleavage of the epidermis resulting from hyperacute epidermal basal cell apoptotic injury. It can be seen typically in classic toxic epidermal necrolysis (TEN), but...

  • High-dose Intravenous Immunoglobulin for Severe Drug Reactions: Efficacy in Toxic Epidermal Necrolysis. Campione, Elena; Marulli, Georgiana Clare; Carrozzo, Anna Maria; Chimenti, Maria Sole; Costanzo, Antonio; Bianchi, Luca // Acta Dermato-Venereologica;Nov2003, Vol. 83 Issue 6, p430 

    High-dose intravenous immunoglobulin has been proposed as an alternative treatment for several immuno-mediated inflammatory skin diseases, usually at a dosage of 1-2 g/kg. We describe the treatment of 10 patients affected by toxic epidermal necrolysis using 400 mg/kg per day on 5 consecutive...

  • INTRAVENOUS IMMUNOGLOBULIN IN DERMATOLOGY. Dhar, Sandipan // Indian Journal of Dermatology;Jan-Mar2009, Vol. 54 Issue 1, p77 

    The article discusses the application of intravenous immunoglobulin (i.v. IG) in dermatology. It explains that an i.v. IG is a sterile highly purified immunoglobulin G preparation that was developed from pooled human plasma and consists of over 95% of unmodified IgG. One study reported the...

  • The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis.  // Current Medical Literature: Dermatology;2012, Vol. 17 Issue 4, p110 

    A review of the article "The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis," by Y. C. Huang which appeared in the "British Journal of Dermatology" is presented.

  • Toxic Epidermal Necrolysis (TEN). Vohr, Hans-Werner // Encyclopedic Reference of Immunotoxicology;2005, p651 

    The entry offers information on toxic epidermal necrolysis (TEN). It is a febrile mucocutaneous syndrome characterized by full-thickness sloughing of the epidermis. Similarities exist between Stevens-Johnson syndrome and TEN in terms of histopathology and responsible drugs.

  • Toxic Epidermal Necrolysis (TEN; Ritter's Disease) and Staphylococcal Scalded Skin Syndrome (SSSS). Koblenzer, Peter J. // Clinical Pediatrics;Aug1976, Vol. 15 Issue 8, p724 

    Focuses on toxic epidermal necrolysis and staphylococcal scalded skin syndrome. History of the disease.

  • Toxic Epidermal Necrolysis (Scalded Skin Syndrome): Report of Two Cases. Baird, Robert L.; Reichelderfer, Thomas E. // Clinical Pediatrics;Jan1963, Vol. 2 Issue 1, p16 

    Reports on cases of children with toxic epidermal necrolysis. Literature review on the disease; Diagnosis of a thermal burn on a 23-month-old female; Blister on a two-and-one-half-year-old Negro boy.

  • Drug-Related Disease is Deadly. Shovlin, Joseph P. // Review of Optometry;6/15/2001, Vol. 138 Issue 6, p111 

    Discusses the key features of toxic epidermal necrolysis. Desquamation of a large area of the skin; Prevention of cytotoxic reactions to drugs; Presence of ocular complications; Reduction of the risk of death.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics